-
Homepagina
-
Hip
-
Knee
-
Ankle
-
Shoulder
-
Elbow
-
Wrist
-
Finger
-
Data Quality
Revision per component name
Knee » Survival TKA » Revision per component name » Cemented primary TKA – overall revision
TABLE Cumulative revision percentages of cemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2022 (n=287,967)
Type of revision (n) | Cumulative revision percentage Kaplan Meier (95% CI) | |||||||||||||||
Femur component | Tibia component | Total primary TKAs (n) | Median (IQR) age (yr) | Total RAs (n) | Total knee (complete revision) | Patella addition | Only femur component | Only tibia component | Only insert/ patella | Missing/ unknown | 1yr | 3yr | 5yr | 7yr | 10yr | 14yr |
All cemented TKAs for osteoarthritis | 287,967 | 69 (63-76) | 12,339 | 4,322 | 2,332 | 501 | 1,079 | 3,799 | 306 | 0.9 (0.9-1.0) | 3.2 (3.1-3.3) | 4.2 (4.1-4.3) | 4.8 (4.8-4.9) | 5.7 (5.6-5.8) | 6.8 (6.6-7.0) | |
Genesis II | Genesis II | 63,915 | 69 (63-75) | 3,101 | 739 | 679 | 235 | 215 | 1.160 | 73 | 1.2 (1.1-1.3) | 3.9 (3.7-4.0) | 5.0 (4.8-5.1) | 5.6 (5.3-5.8) | 6.3 (6.1-6.5) | 7.3 (6.9-7.7) |
NexGen | NexGen | 60,333 | 69 (63-75) | 2,559 | 1,060 | 277 | 74 | 308 | 773 | 67 | 0.9 (0.8-0.9) | 2.8 (2.6-2.9) | 3.8 (3.6-3.9) | 4.7 (4.5-4.9) | 5.9 (5.6-6.1) | 7.2 (6.8-7.6) |
Vanguard Complete Knee | Vanguard Complete Knee | 48,103 | 69 (62-75) | 1,793 | 622 | 332 | 45 | 134 | 617 | 43 | 0.9 (0.8-1.0) | 3.0 (2.8-3.1) | 3.7 (3.5-3.9) | 4.3 (4.1-4.5) | 4.9 (4.7-5.2) | 6.0 (5.5-6.5) |
PFC / SIGMA | PFC / SIGMA | 31,886 | 70 (63-76) | 1,221 | 376 | 276 | 31 | 89 | 418 | 31 | 0.9 (0.8-1.0) | 3.0 (2.8-3.2) | 3.7 (3.5-4.0) | 4.1 (3.8-4.3) | 4.6 (4.4-4.9) | 5.1 (4.7-5.4) |
LCS | LCS | 17,251 | 70 (63-76) | 789 | 413 | 84 | 34 | 145 | 102 | 11 | 0.6 (0.5-0.7) | 3.1 (2.9-3.4) | 4.2 (3.9-4.5) | 4.7 (4.4-5.1) | 5.3 (4.9-5.7) | 5.8 (5.4-6.3) |
Triathlon | Triathlon | 10,507 | 70 (64-76) | 365 | 102 | 60 | 16 | 34 | 148 | 5 | 1.3 (1.1-1.5) | 3.5 (3.1-3.9) | 4.4 (3.9-4.8) | 4.9 (4.4-5.5) | 5.4 (4.8-6.1) | n.a. |
Persona | Persona | 5,811 | 69 (62-74) | 79 | 14 | 10 | 0 | 7 | 47 | 1 | 0.8 (0.6-1.1) | 3.1 (2.1-4.0) | 4.9 (3.1-6.6) | 5.3 (3.4-7.2) | n.a. | n.a. |
Attune | Attune | 5,546 | 70 (63-75) | 73 | 17 | 16 | 3 | 10 | 26 | 1 | 0.6 (0.3-0.8) | 2.3 (1.7-2.9) | 2.9 (2.1-3.6) | 3.1 (2.2-3.9) | n.a. | n.a. |
AGC V2 | AGC V2 | 4,420* | 71 (65-77) | 185 | 106 | 58 | 1 | 2 | 12 | 6 | 0.3 (0.1-0.5) | 2.0 (1.6-2.4) | 2.6 (2.1-3.1) | 3.2 (2.7-3.7) | 3.9 (3.3-4.5) | 5.1 (4.3-5.8) |
balanSys | balanSys | 4,087 | 69 (62-76) | 191 | 64 | 72 | 4 | 11 | 36 | 4 | 0.9 (0.6-1.1) | 3.8 (3.1-4.4) | 4.9 (4.2-5.7) | 5.8 (4.9-6.7) | 6.8 (5.7-7.9) | 8.4 (6.7-10.1) |
TC Plus | TC Plus | 3,729 | 70 (63-76) | 119 | 58 | 32 | 2 | 5 | 17 | 5 | 0.7 (0.4-0.9) | 2.3 (1.8-2.8) | 3.0 (2.4-3.6) | 3.4 (2.8-4.0) | 4.1 (3.3-4.9) | 4.6 (3.6-5.6) |
Optetrak | Optetrak | 3,073* | 70 (62-76) | 385 | 231 | 90 | 3 | 33 | 21 | 7 | 1.1 (0.7-1.4) | 5.3 (4.5-6.1) | 7.1 (6.2-8.0) | 9.1 (8.1-10.2) | 12.4 (11.2-13.7) | 17.5 (15.4-19.6) |
ACS | ACS | 2,684 | 67 (60-73) | 141 | 35 | 22 | 9 | 12 | 55 | 8 | 0.7 (0.4-1.0) | 3.8 (3.0-4.5) | 4.8 (3.9-5.6) | 5.1 (4.3-6.0) | 5.5 (4.6-6.4) | n.a. |
Scorpio NRG | Scorpio | 2,631* | 70 (63-76) | 140 | 49 | 47 | 10 | 4 | 29 | 1 | 0.8 (0.5-1.2) | 3.2 (2.5-3.8) | 4.5 (3.7-5.3) | 5.1 (4.2-6.0) | 5.7 (4.7-6.6) | n.a. |
Scorpio | Scorpio | 2,240* | 71 (63-76) | 117 | 62 | 22 | 3 | 6 | 20 | 4 | 0.3 (0.1-0.5) | 2.4 (1.7-3.0) | 3.2 (2.5-3.9) | 3.7 (2.9-4.5) | 4.7 (3.8-5.6) | 6.0 (4.9-7.1) |
MRK | MRK | 1,610 | 70 (63-76) | 31 | 14 | 8 | 0 | 0 | 8 | 1 | 0.1 (0.0-0.3) | 1.4 (0.7-2.0) | 2.7 (1.6-3.8) | 3.7 (2.3-5.1) | n.a. | n.a. |
Journey BCS | Journey BCS | 1,566 | 69 (62-75) | 138 | 19 | 64 | 1 | 3 | 49 | 2 | 1.0 (0.5-1.5) | 5.5 (4.3-6.8) | 6.8 (5.4-8.2) | 8.7 (7-10.3) | 10.9 (8.9-12.8) | 16.9 (13.4-20.4) |
NexGen GSF | NexGen | 1,252 | 68 (61-74) | 33 | 19 | 5 | 0 | 1 | 7 | 1 | 0.5 (0.1-0.9) | 1.5 (0.8-2.2) | 2.5 (1.6-3.4) | 2.7 (1.8-3.7) | 3.2 (2.1-4.4) | n.a. |
PFC / SIGMA | LCS | 1,212* | 66 (58-75) | 55 | 28 | 11 | 3 | 1 | 10 | 2 | 0.3 (0.0-0.7) | 1.9 (1.1-2.7) | 2.9 (1.9-3.8) | 3.9 (2.7-5.0) | 4.6 (3.3-5.8) | 5.8 (4.1-7.4) |
Journey II BCS | Journey BCS | 1,137 | 65 (60-72) | 72 | 15 | 28 | 0 | 0 | 27 | 2 | 0.4 (0.0-0.7) | 4.5 (3.2-5.8) | 6.0 (4.5-7.4) | 7.0 (5.3-8.7) | n.a. | n.a. |
Innex | Innex | 1,126* | 70 (62-77) | 39 | 14 | 10 | 0 | 4 | 11 | 0 | 1.0 (0.4-1.6) | 2.2 (1.3-3.0) | 2.8 (1.8-3.8) | 3.2 (2.1-4.2) | 3.4 (2.3-4.5) | 3.7 (2.6-4.9) |
Evolution MP | Evolution MP | 946 | 69 (63-74) | 24 | 6 | 9 | 0 | 0 | 8 | 1 | 0.7 (0.1-1.2) | 2.1 (1.1-3.1) | 3.5 (2.0-5.0) | n.a. | n.a. | n.a. |
Profix | Profix | 772* | 68 (61-76) | 60 | 41 | 7 | 2 | 2 | 7 | 1 | 0.5 (0.0-1.0) | 3.7 (2.3-5.0) | 5.6 (3.9-7.2) | 6.6 (4.8-8.3) | 7.7 (5.8-9.6) | 8.5 (6.4-10.6) |
Genesis II | Profix / Genesis MB baseplate | 622* | 67 (60-75) | 66 | 27 | 30 | 0 | 1 | 7 | 1 | 1.0 (0.2-1.8) | 6.9 (4.9-8.9) | 9.0 (6.7-11.3) | 10.3 (7.8-12.7) | 11.2 (8.7-13.8) | 11.2 (8.7-13.8) |
Rotaglide | Rotaglide | 428* | 72 (65-78) | 43 | 29 | 3 | 2 | 0 | 9 | 0 | 0.9 (0.0-1.9) | 4.5 (2.5-6.5) | 5.9 (3.7-8.2) | 7.2 (4.7-9.6) | 10.3 (7.3-13.3) | 12.8 (7.8-17.7) |
Advance MP | Advance | 314* | 71 (65-78) | 33 | 7 | 7 | 1 | 5 | 10 | 3 | 1.9 (0.4-3.4) | 7.7 (4.7-10.6) | 9.0 (5.8-12.1) | 9.3 (6.1-12.5) | 9.7 (6.4-12.9) | n.a. |
Maxim | Vanguard Complete Knee | 272* | 70 (63-77) | 14 | 3 | 3 | 1 | 2 | 5 | 0 | 1.5 (0.0-2.9) | 2.9 (0.9-4.9) | 3.3 (1.2-5.4) | 4.1 (1.7-6.4) | 4.8 (2.3-7.4) | 5.2 (2.5-7.8) |
* Denotes prosthesis combinations with no reported use in primary TKAs in 2022.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; RA: revision arthroplasty; CI: confidence interval; IQR: interquartile range.
© LROI 2023
Only combinations with over 250 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.
Knee » Survival TKA » Revision per component name » Uncemented primary TKA – overall revision
TABLE Cumulative revision percentages of uncemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2022 (n=14,982)
Type of revision (n) | Cumulative revision percentage Kaplan Meier (95% CI) | |||||||||||||||
Femur component | Tibia component | Total primary TKAs (n) | Median (IQR) age (yr) | Total RAs (n) | Total knee (complete revision) | Patella addition | Only femur component | Only tibia component | Only insert/ patella | Missing/ unknown | 1yr | 3yr | 5yr | 7yr | 10yr | 14yr |
All uncemented TKAs for osteoarthritis | 14,982 | 69 (62-75) | 673 | 242 | 99 | 13 | 121 | 190 | 18 | 1.0 (0.8-1.1) | 3.6 (3.3-3.9) | 4.5 (4.1-4.8) | 5.0 (4.6-5.4) | 5.6 (5.2-6.1) | 6.4 (5.8-7.0) | |
LCS | LCS | 9,032 | 69 (63-76) | 403 | 115 | 45 | 9 | 94 | 120 | 4 | 0.9 (0.7-1.1) | 3.5 (3.1-3.9) | 4.2 (3.7-4.6) | 4.5 (4.0-5.0) | 5.0 (4.5-5.5) | 5.4 (4.8-6.0) |
Triathlon | Triathlon | 2,293 | 68 (62-74) | 43 | 14 | 6 | 0 | 3 | 16 | 0 | 0.5 (0.2-0.9) | 1.7 (1.0-2.3) | 2.4 (1.5-3.3) | 2.9 (1.9-3.9) | 3.6 (2.2-4.9) | n.a. |
ACS | ACS | 702 | 69 (61-75) | 32 | 11 | 7 | 1 | 4 | 8 | 0 | 2.0 (0.9-3.1) | 4.6 (2.9-6.3) | 5.1 (3.3-7.0) | 5.4 (3.5-7.3) | n.a. | n.a. |
Attune | Attune | 467 | 67 (61-73) | 12 | 3 | 2 | 0 | 0 | 7 | 0 | 1.2 (0.1-2.3) | 6.1 (2.4-9.8) | n.a. | n.a. | n.a. | n.a. |
Duracon | Duracon | 296* | 69 (61-77) | 10 | 4 | 1 | 0 | 0 | 4 | 0 | 0.4 (0.0-1.0) | 0.7 (0.0-1.7) | 1.4 (0.0-2.8) | 1.4 (0.0-2.8) | 3.1 (1.0-5.1) | 3.5 (1.2-5.7) |
Rotaglide | Rotaglide | 271* | 69 (61-77) | 63 | 40 | 11 | 1 | 1 | 7 | 1 | 1.5 (0.0-3.0) | 10.3 (6.6-14.0) | 16.3 (11.8-20.8) | 19.8 (14.8-24.7) | 22.7 (17.4-28.0) | n.a. |
NexGen | NexGen | 241 | 69 (63-77) | 18 | 8 | 1 | 1 | 3 | 5 | 0 | 1.7 (0.1-3.4) | 5.3 (2.4-8.3) | 7.1 (3.6-10.5) | 8.0 (4.1-11.9) | 9.0 (4.7-13.4) | n.a. |
ACS LD | ACS LD | 249* | 70 (61-76) | 18 | 6 | 3 | 0 | 2 | 3 | 0 | 1.3 (0.0-2.8) | 5.7 (2.7-8.7) | 6.3 (3.1-9.5) | n.a. | n.a. | n.a. |
Genesis II | Genesis II | 234 | 69 (62-75) | 11 | 5 | 2 | 0 | 1 | 1 | 1 | 0.9 (0.0-2.2) | 4.9 (1.9-7.9) | 4.9 (1.9-7.9) | 4.9 (1.9-7.9) | 4.9 (1.9-7.9) | n.a. |
Vanguard Complete Knee | Vanguard Complete Knee | 168 | 67 (61-74) | 15 | 7 | 2 | 0 | 4 | 1 | 0 | 2.5 (0.1-4.9) | 5.7 (2.1-9.4) | 5.7 (2.1-9.4) | 7.6 (3.2-12) | 10.1 (4.6-15.6) | n.a. |
Triathlon | Triathlon Tritanium | 112 | 69 (64-72) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
* Denotes prosthesis combinations with no reported use in primary TKAs in 2022.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; RA: revision arthroplasty; CI: confidence interval; IQR: interquartile range.
© LROI 2023
Only combinations with over 100 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.
Knee » Survival TKA » Revision per component name » Cemented primary TKA – major revision
TABLE Cumulative major revision percentages of cemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2022 (n=287,967)
Cumulative major revision percentage Kaplan Meier (95% CI) | ||||||||||
Femur component | Tibia component | Total primary TKAs (n) | Median (IQR) age (yr) | Major revision¹ arthroplasties (n) | 1yr | 3yr | 5yr | 7yr | 10yr | 14yr |
All cemented TKAs for osteoarthritis | 287,967 | 69 (63-76) | 6,576 | 0.3 (0.3-0.4) | 1.5 (1.5-1.6) | 2.1 (2.1-2.2) | 2.6 (2.5-2.7) | 3.2 (3.1-3.3) | 3.9 (3.8-4.0) | |
Genesis II | Genesis II | 63,915 | 69 (63-75) | 1,359 | 0.4 (0.3-0.4) | 1.6 (1.5-1.7) | 2.2 (2.0-2.3) | 2.5 (2.4-2.6) | 2.9 (2.7-3.0) | 3.2 (2.9-3.4) |
NexGen | NexGen | 60,333 | 69 (63-75) | 1,578 | 0.3 (0.3-0.4) | 1.4 (1.3-1.5) | 2.1 (2.0-2.2) | 2.9 (2.7-3.0) | 3.9 (3.7-4.1) | 4.9 (4.6-5.3) |
Vanguard Complete Knee | Vanguard Complete Knee | 48,103 | 69 (62-75) | 913 | 0.4 (0.3-0.4) | 1.4 (1.3-1.5) | 1.9 (1.7-2.0) | 2.2 (2.0-2.3) | 2.6 (2.4-2.8) | 3.2 (2.9-3.6) |
PFC / SIGMA | PFC / SIGMA | 31,886 | 70 (63-76) | 560 | 0.3 (0.2-0.3) | 1.2 (1.1-1.3) | 1.7 (1.5-1.8) | 1.9 (1.7-2.0) | 2.2 (2.0-2.3) | 2.4 (2.2-2.6) |
LCS | LCS | 17,251 | 70 (63-76) | 627 | 0.4 (0.3-0.5) | 2.3 (2.1-2.5) | 3.2 (2.9-3.5) | 3.8 (3.5-4.1) | 4.3 (4.0-4.7) | 4.8 (4.4-5.2) |
Triathlon | Triathlon | 10,507 | 70 (64-76) | 167 | 0.4 (0.3-0.6) | 1.5 (1.2-1.8) | 2.1 (1.8-2.5) | 2.4 (2.0-2.8) | 2.7 (2.2-3.2) | n.a. |
Persona | Persona | 5,811 | 69 (62-74) | 25 | 0.3 (0.1-0.4) | 1.0 (0.4-1.6) | 2.3 (0.9-3.7) | 2.8 (1.1-4.6) | n.a. | n.a. |
Attune | Attune | 5,546 | 70 (63-75) | 32 | 0.2 (0.1-0.3) | 1.0 (0.6-1.4) | 1.4 (0.9-1.9) | 1.4 (0.9-1.9) | n.a. | n.a. |
AGC V2 | AGC V2 | 4,420* | 71 (65-77) | 116 | 0.1 (0.0-0.2) | 1.1 (0.8-1.4) | 1.5 (1.1-1.9) | 1.9 (1.5-2.4) | 2.4 (1.9-2.9) | 3.2 (2.6-3.8) |
balanSys | balanSys | 4,087 | 69 (62-76) | 86 | 0.3 (0.1-0.4) | 1.4 (1.0-1.8) | 2.2 (1.7-2.7) | 2.8 (2.2-3.5) | 3.3 (2.5-4.0) | 3.7 (2.7-4.7) |
¹ Revision of at least the femur or tibia component.
* Denotes prosthesis combinations with no reported use in primary TKAs in 2022.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; CI: confidence interval; IQR: interquartile range.
© LROI 2023
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.
Knee » Survival TKA » Revision per component name » Uncemented primary TKA – major revision
TABLE Cumulative major revision percentages of uncemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2022 (n=14,982)
Cumulative major revision percentage Kaplan Meier (95% CI) | ||||||||||
Femur component | Tibia component | Total primary TKAs (n) | Median (IQR) age (yr) | Major revision¹ arthroplasties (n) | 1yr | 3yr | 5yr | 7yr | 10yr | 14yr |
All uncemented TKAs for osteoarthritis | 14,982 | 69 (62-75) | 414 | 0.6 (0.5-0.7) | 2.1 (1.9-2.4) | 2.7 (2.4-3.0) | 3.1 (2.8-3.4) | 3.5 (3.2-3.9) | 4.0 (3.5-4.5) | |
LCS | LCS | 9,032 | 69 (63-76) | 237 | 0.6 (0.4-0.7) | 2.2 (1.8-2.5) | 2.7 (2.3-3.0) | 2.8 (2.4-3.2) | 3.0 (2.6-3.4) | 3.3 (2.8-3.7) |
Triathlon | Triathlon | 2,293 | 68 (62-74) | 20 | 0.3 (0.0-0.5) | 0.6 (0.2-1.0) | 1.1 (0.5-1.7) | 1.5 (0.7-2.2) | 2.5 (1.1-3.8) | n.a. |
ACS | ACS | 702 | 69 (61-75) | 18 | 1.4 (0.5-2.4) | 2.7 (1.4-4.1) | 3 (1.6-4.4) | 3.3 (1.8-4.8) | n.a. | n.a. |
Attune | Attune | 467 | 67 (61-73) | 3 | 0.2 (0.0-0.7) | 1.4 (0.0-3.1) | n.a. | n.a. | n.a. | n.a. |
Duracon | Duracon | 296* | 69 (61-77) | 4 | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.4 (0.0-1.1) | 0.4 (0.0-1.1) | 1.6 (0.0-3.1) | 1.6 (0.0-3.1) |
Rotaglide | Rotaglide | 271* | 69 (61-77) | 49 | 0.4 (0.0-1.1) | 6.5 (3.5-9.5) | 11.3 (7.4-15.2) | 15.2 (10.7-19.6) | 18.1 (13.2-23) | n.a. |
NexGen | NexGen | 241 | 69 (63-77) | 13 | 1.3 (0.0-2.8) | 4.0 (1.4-6.6) | 5.0 (2.1-7.9) | 5.9 (2.5-9.3) | 5.9 (2.5-9.3) | n.a. |
ACS LD | ACS LD | 249* | 70 (61-76) | 9 | 1.3 (0.0-2.8) | 3.5 (1.1-5.9) | 4.1 (1.5-6.7) | n.a. | n.a. | n.a. |
Genesis II | Genesis II | 234 | 69 (62-75) | 6 | 0.5 (0.0-1.3) | 3.0 (0.6-5.3) | 3.0 (0.6-5.3) | 3.0 (0.6-5.3) | 3.0 (0.6-5.3) | n.a. |
Vanguard Complete Knee | Vanguard Complete Knee | 168 | 67 (61-74) | 11 | 1.9 (0.0-4.0) | 4.5 (1.2-7.7) | 4.5 (1.2-7.7) | 5.5 (1.7-9.2) | 8.0 (3.0-13.1) | n.a. |
¹ Revision of at least the femur or tibia component.
* Denotes prosthesis combinations with no reported use in primary TKAs in 2022.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; CI: confidence interval; IQR: interquartile range.
© LROI 2023
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.
Knee » Survival TKA » Revision per component name » Bone cement
TABLE Cumulative revision percentages of the most frequently registered types of bone cement by type of mixing system in primary total knee arthroplasties in the Netherlands in 2007-2022
Cumulative revision percentage Kaplan Meier (95% CI) | ||||||||
Bone cement | Total primary TKAs (n) | Total RAs (n) | 1yr | 3yr | 5yr | 7yr | 10yr | 14yr |
Separately packed | 186,441 | 9,094 | 0.9 (0.9-1.0) | 3.3 (3.2-3.4) | 4.3 (4.2-4.4) | 5.0 (4.9-5.1) | 5.9 (5.7-6.0) | 6.9 (6.7-7.1) |
Palacos R+G | 139,537 | 6,691 | 0.9 (0.9-1.0) | 3.3 (3.2-3.4) | 4.3 (4.2-4.4) | 5.0 (4.8-5.1) | 5.8 (5.7-6.0) | 6.9 (6.6-7.1) |
Refobacin Bone Cement R | 13,142 | 680 | 0.8 (0.6-0.9) | 3.0 (2.7-3.3) | 4.0 (3.7-4.4) | 5.1 (4.7-5.5) | 6.6 (6.1-7.1) | 8.0 (7.3-8.7) |
Palacos MV+G | 8,394 | 382 | 0.8 (0.6-1.0) | 3.1 (2.7-3.4) | 4.1 (3.6-4.5) | 4.8 (4.4-5.3) | 5.3 (4.7-5.8) | n.a. |
Simplex ABC EC | 5,374 | 367 | 1.0 (0.8-1.3) | 3.9 (3.4-4.4) | 5.2 (4.6-5.8) | 6.2 (5.6-6.9) | 7.3 (6.5-8.0) | 8.7 (7.4-10.0) |
Simplex ABC TOBRA | 5,165 | 232 | 0.8 (0.5-1.0) | 2.2 (1.8-2.6) | 3.0 (2.5-3.5) | 3.6 (3.1-4.1) | 4.7 (4.0-5.3) | 6.5 (5.2-7.8) |
Refobacin Plus Bone Cement | 3,163 | 205 | 1.1 (0.7-1.4) | 4.4 (3.6-5.1) | 5.4 (4.6-6.2) | 5.9 (5.1-6.8) | 6.5 (5.6-7.3) | 7.1 (6.1-8.1) |
Palacos R | 1,753 | 80 | 0.6 (0.2-0.9) | 2.6 (1.8-3.4) | 3.3 (2.4-4.1) | 3.9 (3.0-4.8) | 4.7 (3.6-5.7) | 5.3 (4.1-6.5) |
Subiton G | 1,550 | 53 | 1.4 (0.8-2.1) | 4.9 (3.5-6.3) | n.a. | n.a. | n.a. | n.a. |
Biomet Plus Bone Cement | 1,472 | 66 | 1.0 (0.5-1.5) | 3.5 (2.5-4.4) | 4.4 (3.3-5.5) | 4.6 (3.5-5.7) | 5.0 (3.7-6.2) | n.a. |
Palamed G | 1,430 | 60 | 0.2 (0.0-0.4) | 2.3 (1.5-3.0) | 3.1 (2.2-4.1) | 3.5 (2.6-4.5) | 4.0 (3.0-5.0) | 4.7 (3.5-5.9) |
Biomet Bone Cement R | 884 | 23 | 0.8 (0.2-1.4) | 3.6 (1.9-5.4) | 4.7 (2.4-6.9) | 5.6 (2.7-8.5) | 5.6 (2.7-8.5) | n.a. |
Versabond | 647 | 51 | 0.6 (0.0-1.2) | 5.3 (3.6-7.0) | 6.3 (4.4-8.1) | 6.8 (4.8-8.7) | 7.3 (5.3-9.3) | n.a. |
cemSys 1G | 636 | 46 | 1.4 (0.5-2.3) | 3.8 (2.3-5.3) | 6.2 (4.3-8.1) | 7.2 (5.1-9.3) | n.a. | n.a. |
Simplex P | 409 | 22 | 0 (0-0) | 2.8 (1.2-4.4) | 3.8 (1.9-5.7) | 4.4 (2.3-6.4) | 5.3 (3.0-7.5) | 6.1 (3.6-8.6) |
Simplex HV | 382 | 8 | 0.8 (0.0-1.7) | 2.0 (0.5-3.5) | 3.2 (0.4-6.0) | n.a. | n.a. | n.a. |
Synicem1G | 339 | 12 | 0.6 (0.0-1.4) | 3.6 (1.6-5.6) | 3.6 (1.6-5.6) | n.a. | n.a. | n.a. |
Palamed | 250 | 14 | 0.8 (0.0-1.9) | 2.8 (0.8-4.8) | 4.0 (1.6-6.4) | 4.9 (2.2-7.5) | 5.3 (2.5-8.1) | 5.8 (2.8-8.8) |
Pre-packed in a vacuum mixing system | 96,573 | 3,230 | 1.0 (1.0-1.1) | 3.3 (3.2-3.4) | 4.2 (4-4.3) | 4.8 (4.6-5.0) | 5.6 (5.3-5.8) | 6.8 (5.9-7.6) |
Refobacin Bone Cement R | 43,169 | 1,453 | 1.1 (1.0-1.2) | 3.2 (3.1-3.4) | 4.2 (3.9-4.4) | 4.9 (4.6-5.2) | 5.6 (5.3-6.0) | n.a. |
Palacos R+G | 35,186 | 974 | 1.1 (1.0-1.2) | 3.3 (3.1-3.6) | 4.1 (3.9-4.4) | 4.7 (4.3-5.1) | n.a. | n.a. |
Refobacin Plus Bone Cement | 16,356 | 687 | 0.7 (0.6-0.9) | 3.2 (2.9-3.5) | 4.0 (3.7-4.3) | 4.5 (4.2-4.9) | 5.3 (4.9-5.7) | 6.7 (5.5-7.9) |
Cemex Genta | 1,444* | 100 | 1.0 (0.5-1.6) | 4.9 (3.8-6.0) | 5.6 (4.4-6.8) | 6.2 (5.0-7.5) | 7.2 (5.8-8.6) | n.a. |
* Denotes types of bone cement with no reported use in primary TKAs in 2022.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; RA: revision arthroplasy; CI: confidence interval; IQR: interquartile range.
© LROI 2023